PolyPid Completes Enrollment for SHIELD II Interim Analysis, Eyes Early Conclusion on Surgical Infection Prevention Trial
Portfolio Pulse from Benzinga Newsdesk
PolyPid Ltd. has completed patient enrollment for an interim analysis in its SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections. The analysis could lead to early trial conclusion, continuation, or futility. Successful results may unlock additional funding.
October 01, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PolyPid has completed enrollment for an interim analysis in its SHIELD II Phase 3 trial. Positive results could lead to early trial conclusion and unlock up to $24.6M in funding, potentially impacting stock prices.
The completion of enrollment for the interim analysis is a significant milestone for PolyPid. If the analysis shows positive efficacy, it could lead to early trial conclusion and unlock substantial funding, which would be a positive catalyst for the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100